News & Events

Oct 06, 2021

We are delighted to announce that Novai has been short listed in the top 3 Best Biotech Start Up's in the OBN Awards.

Congratulations to the other finalists, SENISCA and SwitchRx for their nominations. Looking forward to celebrating UK biotech success in Oxford in November.

Sep 22, 2021

Novai are delighted to be collaborating with Heidelberg Engineering on DARC Clinical Trials

Redefining Clinical Trials

Aug 31, 2021

ONL Therapeutics and Novai are pleased to announce the start of a Phase 1b clinical trial of ONL1204 Ophthalmic Solution in patients with geographic atrophy (GA) associated with age-related macular degeneration (AMD) using DARC as an exploratory endpoint to measure the impact of ONL1204 on protecting retinal cells. The clinical trial is being run by leading contract research organisation, Novotech

Aug 24, 2021

Novai is pleased to announce that our CSO, Professor Cordeiro has been featured in the TOP LIST of Excellent Women in European Vision Research and The Ophthalmologist Top 100 Women in Ophthalmology Power List 2021.

Aug 12, 2021

It's been an exciting year so far here at Novai, as we have injected the first commercial AMD patient with our biomarker, DARC.

May 26, 2021

DARC (Detection of Apoptosing Retinal Cells) is a retinal imaging technology that has been developed within the last 2 decades from basic laboratory science to Phase 2 clinical trials. The paper, in the highest impact factor journal in ophthalmology, highlights the recent clinical results using the AI algorithm, but also covers the development history and science behind DARC.

Apr 30, 2021

Novai is happy to introduce DARC Stratos: a cloud based Artificial Intelligence platform running on Amazon Web Services. Funded by Innovate UK, DARC Stratos offers a robust and scalable platform for analysis of DARC images, allowing the remote capture of clinical data in a secure and compliant manner.

Mar 1, 2021

Novai has been awarded a £1.2M Biomedical Catalyst grant from Innovate UK to further develop the DARC platform capabilities. Novai is committed to improving patients' outcomes and this grant will accelerate those possibilities.

Feb 12, 2021

Novai is pleased to announce the completion of a £1M funding round led by SFC, which included a number of overseas institutional funds investing in the company for the first time along with participation from a number of strategic angel investors.

Feb 5, 2021

We are delighted to announce that Novai has won Best Newcomer in the Clinical Trials Excellence Awards for 2020.

Jan 15, 2021

We are honoured to be invited to present at the 10th Annual New Horizons Forum organised by Glaucoma Research Foundation. Novai's video is publicly available now on Glaucoma 360 website under the Video on Demand tab.

Dec 18, 2020

A newly published study conducted by Professor Francesca Cordeiro, CSO of Novai, found that DARC technology can predict wet AMD lesions up to 36 months in advance of them occurring. This revolutionary finding addresses the challenge of identifying the disease prior to vision loss - read the full paper in the Expert Review of Molecular Diagnostics.

Dec 9, 2020

We are delighted to announce our first research collaboration with PINOTBIO, Inc., South Korea. We look forward to working with them using DARC technology.

Nov 13, 2020

We're thrilled to share the news that out of 1500 applicants, we placed second in the finals of the Shenzhen Innovation & Entrepreneurship International Competition 2020.

Nov 11, 2020

We’re thrilled to announce that we have been awarded an Innovate UK grant to further develop our AI cloud system, enabling DARC technology to be interfaced into existing clinical trial systems.

Oct 10, 2020

We’re pleased to announce that we won the UK Division of the Shenzhen Innovation & Entrepreneurship Competition 2020.

Join our Chief Scientific Officer, Professor Francesca Cordeiro as she discusses the findings of our brand new Phase II clinical trial results, published online today

May 3, 2020

“These results are very promising as they show DARC could be used as a biomarker when combined with the AI-aided algorithm.” Explore the results of our Phase II trial in the Expert Review of Molecular Diagnostics.

April 14, 2020

We are delighted to announce our first research collaboration with Santen USA. We look forward to embarking upon this joint venture of innovation